# GIM-122

Source: https://onco.cc/drugs/gim-122/  
OnCo record `gim-122` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

GIM-122 is an experimental humanised IgG1 kappa dual-functioning monoclonal antibody from Georgiamune, in phase 1 trials for advanced solid malignancies.

## Summary

GIM-122 (GIM122) is a humanised IgG1 kappa dual-functioning monoclonal antibody from Georgiamune. A dual-functioning antibody that the company says overcomes cancer-mediated immune suppression and at the same time stimulates activated T cells; targets not disclosed. Its furthest stage is phase 1, for advanced solid malignancies. ClinicalTrials.gov registers it in one study linked below. FDA IND clearance August 2023; phase 1/2 recruiting per registry (NCT06028074). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: GIM122
- Tags: pipeline; ctgov-ingest
- Code: GIM-122
- Modality: Humanised IgG1 kappa dual-functioning monoclonal antibody
- Mechanism: A dual-functioning antibody that the company says overcomes cancer-mediated immune suppression and at the same time stimulates activated T cells; targets not disclosed.

## Sources

- Georgiamune: georgiamune.com: https://www.georgiamune.com/pipeline
- Georgiamune: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06028074
- ClinicalTrials.gov: trials of GIM-122: https://clinicaltrials.gov/search?intr=GIM-122

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Georgiamune](https://onco.cc/companies/georgiamune/)
- trials: [Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies](https://onco.cc/trials/nct06028074/)

---
JSON: https://onco.cc/api/v1/entities/gim-122.json